Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saci-IO TNBC
NCT04468061Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Sacituzumab Govitecan + Pembrolizumab with Sacituzumab Govitecan (2 arms). Primary endpoint: Progression Free Survival at 3 years. Started Jul 2020; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04468061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468061.